H.C. Wainwright initiated coverage of Serina Therapeutics (SER) with a Buy rating and $15 price target The firm says Serina is an emerging biopharmaceutical company focused on developing next-generation versions of existing active pharmaceutical ingredients.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SER: